Healthcare
Exclusive insider sentiment analysis for the Healthcare sector. Track real-time Director purchases and institutional money flow to identify high-conviction opportunities before the market reacts.
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-03 11:29 | 2026-04-01 | RMD | RESMED INC | Sandercock Brett | Officer; Chief Financial Officer | Medical Instruments & Supplies | SALE | $224.31 | 1,000 | $224,310 | 83,495 | -1.2% |
| 2026-04-03 11:29 | 2026-04-01 | CGEN | COMPUGEN LTD | Ophir Eran | Director, Officer; President and CEO | Biotechnology | OPT+S | $2.21 | 5,625 | $12,413 | 11,375 | -33.1% |
| 2026-04-03 11:31 | 2026-04-01 | CGEN | COMPUGEN LTD | Levine Zurit | Officer; SVP, Business Development | Biotechnology | OPT+S | $2.20 | 3,500 | $7,700 | 29,375 | -10.6% |
| 2026-04-02 20:06 | 2026-04-01 | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | Officer; SVP, Finance | Biotechnology | OPT+S | $29.44 | 2,500 | $73,611 | 12,965 | -16.2% |
| 2026-04-02 20:08 | 2026-04-01 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Officer; President, R&D & CMO | Biotechnology | OPT+S | $29.46 | 15,000 | $441,905 | 0 | -100.0% |
| 2026-04-02 21:58 | 2026-04-01 | RPRX | Royalty Pharma plc | Coyne Terrance P. | Officer; EVP & CFO | Biotechnology | SALE | $48.33 | 34,791 | $1,681,512 | 32,916 | -51.4% |
| 2026-04-02 20:16 | 2026-03-31 | CGC | Canopy Growth Corp | Yanofsky Theresa | Director | Drug Manufacturers - Specialty & Generic | SALE | $0.93 | 10,373 | $9,647 | 53,145 | -16.3% |
| 2026-04-02 20:15 | 2026-03-31 | CGC | Canopy Growth Corp | Lazzarato David Angelo | Director | Drug Manufacturers - Specialty & Generic | SALE | $0.93 | 15,624 | $14,530 | 72,048 | -17.8% |
| 2026-04-02 20:47 | 2026-03-31 | ALLO | Allogene Therapeutics, Inc. | Beneski Benjamin Machinas | Officer; SVP, Chief Technical Officer | Biotechnology | SALE | $2.50 | 2,867 | $7,168 | 195,338 | -1.4% |
| 2026-04-02 20:39 | 2026-04-01 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | Officer; Chief Financial Officer | Biotechnology | SALE | $12.95 | 2,500 | $32,375 | 119,010 | -2.1% |
| 2026-04-02 21:12 | 2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Neal James R | Director | Biotechnology | BUY | $2.54 | 789 | $2,000 | 818 | +2,720.7% |
| 2026-04-02 21:55 | 2026-04-01 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | Director, Officer; CHIEF EXECUTIVE OFFICER | Biotechnology | OPT+S | $30.93 | 60,000 | $1,855,842 | 432,886 | -12.2% |
| 2026-04-02 20:29 | 2026-04-01 | BMY | BRISTOL MYERS SQUIBB CO | Elkins David V | Officer; EVP, Chief Financial Officer | Drug Manufacturers - General | SALE | $61.67 | 30,000 | $1,850,016 | 159,248 | -15.9% |
| 2026-04-02 21:13 | 2026-04-01 | AMWL | American Well Corp | Zamansky Dmitry | Officer; Chief Product & Tech. Officer | Health Information Services | SALE | $5.30 | 5,575 | $29,548 | 241,080 | -2.3% |
| 2026-04-02 21:11 | 2026-04-01 | AMWL | American Well Corp | McNeice Paul Francis | Officer; Chief Accounting Officer | Health Information Services | SALE | $5.30 | 383 | $2,030 | 10,616 | -3.5% |
| 2026-04-02 21:55 | 2026-04-01 | TVTX | Travere Therapeutics, Inc. | REED ELIZABETH E | Officer; Chief Legal Officer and GC | Biotechnology | OPT+S | $30.00 | 10,000 | $300,000 | 105,211 | -8.7% |
| 2026-04-02 20:16 | 2026-03-31 | CGC | Canopy Growth Corp | ATKINS M SHAN | Director | Drug Manufacturers - Specialty & Generic | SALE | $0.93 | 2,074 | $1,929 | 41,390 | -4.8% |
| 2026-04-02 20:15 | 2026-03-31 | CGC | Canopy Growth Corp | BAYERN JOSEPH | Director | Drug Manufacturers - Specialty & Generic | SALE | $0.93 | 2,658 | $2,472 | 40,000 | -6.2% |
| 2026-04-02 21:13 | 2026-04-02 | EW | Edwards Lifesciences Corp | BOBO DONALD E JR | Officer; CVP,Strategy/Corp Development | Medical Devices | OPT+S | $80.16 | 22,680 | $1,818,056 | 21,266 | -51.6% |
| 2026-04-03 01:00 | 2026-03-31 | ADCT | ADC Therapeutics SA | Redmile Group, LLC | 10% owner | Biotechnology | SALE | $3.34 | 5,880,415 | $19,636,470 | 10,265,297 | -36.4% |
| 2026-04-03 00:26 | 2026-04-02 | KOD | Kodiak Sciences Inc. | BORGESON JOHN A. | Officer; Chief Financial Officer | Biotechnology | OPT+S | $39.92 | 30,000 | $1,197,489 | 183,316 | -14.1% |
| 2026-04-03 00:07 | 2026-04-01 | HNGE | Hinge Health, Inc. | Mecklenburg Gabriel M.I. | Director, Other | Health Information Services | SALE | $38.46 | 50,000 | $1,922,780 | 0 | -100.0% |
| 2026-04-03 00:09 | 2026-04-01 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Officer; President, R&D | Biotechnology | OPT+S | $21.20 | 27,000 | $572,478 | 112,622 | -19.3% |
| 2026-04-02 23:43 | 2026-04-01 | LGND | LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W | Director | Biotechnology | SALE | $202.23 | 467 | $94,440 | 42,253 | -1.1% |
| 2026-04-02 23:43 | 2026-04-02 | IONS | IONIS PHARMACEUTICALS INC | Devers Shannon L. | Officer; EVP, Chief Human Resources Ofc | Biotechnology | SALE | $74.05 | 6,193 | $458,613 | 16,348 | -27.5% |
| 2026-04-02 23:43 | 2026-04-01 | IONS | IONIS PHARMACEUTICALS INC | KLEIN JOSEPH III | Director | Biotechnology | OPT+S | $75.55 | 22,321 | $1,686,302 | 11,014 | -67.0% |
| 2026-04-02 23:34 | 2026-03-31 | VVOS | Vivos Therapeutics, Inc. | Skaff Michael C | 10% owner | Medical Devices | BUY | $1.34 | 1,353,625 | $1,813,858 | 1,353,625 | +100.0% |
| 2026-04-02 23:16 | 2026-04-01 | ADPT | Adaptive Biotechnologies Corp | RUBINSTEIN JULIE | Officer; President and COO | Biotechnology | OPT+S | $14.53 | 38,120 | $553,693 | 447,202 | -7.9% |
| 2026-04-02 22:53 | 2026-03-31 | MLYS | Mineralys Therapeutics, Inc. | Karydas Daphne | Director | Biotechnology | OPT+S | $25.00 | 3,000 | $75,000 | 6,200 | -32.6% |
| 2026-04-02 22:54 | 2026-03-31 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | Director, Officer; Chief Executive Officer | Biotechnology | SALE | $26.27 | 75,000 | $1,970,520 | 705,051 | -9.6% |
| 2026-04-02 22:56 | 2026-04-01 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | Officer; CLO & Secretary | Biotechnology | OPT+S | $201.24 | 5,000 | $1,006,224 | 41,382 | -10.8% |
| 2026-04-02 23:02 | 2026-04-02 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | Officer; Chief Legal Officer | Biotechnology | SALE | $15.24 | 8,148 | $124,149 | 26,453 | -23.5% |
| 2026-04-02 22:45 | 2026-03-31 | PHR | Phreesia, Inc. | Pale Fire Capital SE | 10% owner | Health Information Services | BUY | $8.20 | 1,275,500 | $10,464,840 | 8,924,329 | +16.7% |
| 2026-04-02 22:28 | 2026-04-01 | HALO | HALOZYME THERAPEUTICS, INC. | Torley Helen | Director, Officer; PRESIDENT AND CEO | Biotechnology | OPT+S | $64.81 | 40,000 | $2,592,236 | 767,780 | -5.0% |
| 2026-04-02 22:15 | 2026-04-01 | TERN | Terns Pharmaceuticals, Inc. | Kuriakose Emil | Officer; Chief Medical Officer | Biotechnology | SALE | $52.75 | 942 | $49,693 | 105,673 | -0.9% |
| 2026-04-02 22:19 | 2026-04-01 | RARE | Ultragenyx Pharmaceutical Inc. | Horn Howard | Officer; Chief Financial Officer | Biotechnology | SALE | $20.97 | 4,683 | $98,203 | 80,351 | -5.5% |
| 2026-04-02 21:20 | 2026-04-01 | AMWL | American Well Corp | Gotlib Phyllis | Officer; President, International | Health Information Services | SALE | $5.30 | 3,706 | $19,642 | 163,004 | -2.2% |
| 2026-04-02 21:02 | 2026-03-31 | ZBIO | Zenas BioPharma, Inc. | Lu Hongbo | Director | Biotechnology | BUY | $18.63 | 3,768 | $70,198 | 426,736 | +0.9% |
| 2026-04-02 21:05 | 2026-04-02 | LPCN | Lipocine Inc. | Patel Mahesh V. | Director, Officer; Chief Executive Officer | Biotechnology | BUY | $2.02 | 25,000 | $50,500 | 135,679 | +22.6% |
| 2026-04-02 20:48 | 2026-03-31 | MLTX | MoonLake Immunotherapeutics | BVF PARTNERS L P/IL | Director, 10% owner | Biotechnology | SALE | $16.79 | 3,750,000 | $62,962,500 | 1,039,238 | -78.3% |
| 2026-04-02 20:34 | 2026-03-31 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $585.76 | 9,500 | $5,564,709 | 40,513 | -19.0% |
| 2026-04-02 20:35 | 2026-04-01 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $581.63 | 9,500 | $5,525,526 | 40,513 | -19.0% |
| 2026-04-02 20:36 | 2026-04-02 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer; EVP & GENERAL COUNSEL | Drug Manufacturers - Specialty & Generic | OPT+S | $565.87 | 8,300 | $4,696,690 | 45,172 | -15.5% |
| 2026-04-02 20:05 | 2026-04-01 | TARA | Protara Therapeutics, Inc. | Zummo Jacqueline | Officer; Chief R&D Officer | Biotechnology | SALE | $5.26 | 22,598 | $118,865 | 95,961 | -19.1% |
| 2026-04-02 20:05 | 2026-03-31 | CELC | Celcuity Inc. | Buller Richard E | Director | Biotechnology | OPT+S | $110.27 | 3,000 | $330,804 | 6,760 | -30.7% |
| 2026-04-02 20:05 | 2026-04-01 | FENC | FENNEC PHARMACEUTICALS INC. | Raykov Rosty | Director | Biotechnology | OPT+S | $6.31 | 10,946 | $69,069 | 113,856 | -8.8% |
| 2026-04-02 17:52 | 2026-04-01 | RMD | RESMED INC | FARRELL PETER C | Director | Medical Instruments & Supplies | SALE | $225.00 | 2,000 | $450,000 | 60,773 | -3.2% |
| 2026-04-02 17:01 | 2026-04-01 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | Officer; CMO | Biotechnology | OPT+S | $32.31 | 28,662 | $926,095 | 9,597 | -74.9% |
| 2026-04-02 16:00 | 2026-03-31 | KRRO | Korro Bio, Inc. | Lynx1 Capital Management LP | 10% owner | Biotechnology | BUY | $10.60 | 520 | $5,512 | 1,538,296 | +0.0% |
| 2026-04-02 14:46 | 2026-04-01 | VIR | Vir Biotechnology, Inc. | SATO VICKI L | Director | Biotechnology | SALE | $9.07 | 22,000 | $199,617 | 1,100,391 | -2.0% |
Strategic Analysis
Analyzing insider transactions within the Healthcare sector provides critical insights into institutional sentiment. When multiple executives across different companies in the same industry exhibit similar buying patterns (cluster buying), it often signals an upcoming sector-wide recovery or undervalued market conditions.
Regulatory Transparency
Our platform tracks SEC Form 4 filings in real-time. We differentiate between routine option exercises and open-market purchases to give you a clear view of "Skin in the Game". Understanding the roles of Directors vs. 10% Owners helps prioritize signals that carry the most predictive weight.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.